Floatz logo

MITOMYCIN C

Peritoneal Carcinomatosis

H. Lee Moffitt Cancer Center and Research InstituteSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
81/ 100

Competitive context

32 Active assets in the Peritoneal Carcinomatosis cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ciusss de L'Est de l'Île de Montréal
Phase 3BB
Eloxatin
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BB
Irinotecan
Catharina Ziekenhuis Eindhoven
Phase 3BB
Irinotecan
Catharina Ziekenhuis Eindhoven
Phase 3BB

View all 42 →

Same molecule, other indications

MITOMYCIN C is also rated in:

appendix carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
colorectal carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
anal carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →